TY - JOUR
T1 - Integration of trastuzumab into adjuvant systemic therapy of breast cancer
T2 - Ongoing and planned clinical trials
AU - Hortobagyi, Gabriel N.
AU - Perez, Edith A.
N1 - Funding Information:
Dr Hortobagyi has received research grant support from Bristol-Myers Squibb and Ribozyme Pharmaceuticals. He has received honoraria from AstraZeneca, Auentis, Bristol-Myers Squibb, Ge-nentech, Nouartis, Pharmacia, and Ribozyme Phavnaceuticals, and has served as a consuht to Agouron, Genentech, Nouartis, and Ribozyme Pharmaceuticals.
Copyright:
Copyright 2020 Elsevier B.V., All rights reserved.
PY - 2001
Y1 - 2001
N2 - Clinical trials using the humanized version of the antiHER2 murine monoclonal antibody 4D5, trastuzumab, have shown antitumor activity in patients with HER2-positive metastatic breast cancer. Improved response and survival rates have been shown when trastuzumab was added to first-line combination chemotherapy with anthracycline/cyclophosphamide or paclitaxel compared with the same chemotherapy alone. Because of the promising safety and efficacy profile of trastuzumab in the metastatic setting, this novel biologic has now entered adjuvant breast cancer trials in both the United States and Europe. Five clinical trials are discussed in this report, capturing the evolving role of trastuzumab as adjuvant therapy for breast cancer.
AB - Clinical trials using the humanized version of the antiHER2 murine monoclonal antibody 4D5, trastuzumab, have shown antitumor activity in patients with HER2-positive metastatic breast cancer. Improved response and survival rates have been shown when trastuzumab was added to first-line combination chemotherapy with anthracycline/cyclophosphamide or paclitaxel compared with the same chemotherapy alone. Because of the promising safety and efficacy profile of trastuzumab in the metastatic setting, this novel biologic has now entered adjuvant breast cancer trials in both the United States and Europe. Five clinical trials are discussed in this report, capturing the evolving role of trastuzumab as adjuvant therapy for breast cancer.
UR - http://www.scopus.com/inward/record.url?scp=0035170656&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0035170656&partnerID=8YFLogxK
U2 - 10.1053/sonc.2001.28549
DO - 10.1053/sonc.2001.28549
M3 - Article
C2 - 11706395
AN - SCOPUS:0035170656
SN - 0093-7754
VL - 28
SP - 41
EP - 46
JO - Seminars in oncology
JF - Seminars in oncology
IS - 5 SUPPL. 16
ER -